Castellano | Euskara | Français | English
DAR No 1. Aclidinium, as maintenance therapy in the management of COPD (Bretaris Genuair®, Eklira Genuair®)
Share it
Besides an anticholinergic agent, what else do we know about this drug?
- There is no head-to-head trial comparing aclidinium vs other long-acting bronchodilators.
- Compared to placebo, aclidinium 400 mcg/12h improves spirometry parameters although the clinical relevance of this improvement is modest.
- Adverse effects related to heart conduction have been reported, and the EMA has requested a post-approval study to monitor cardiovascular events.
- It should be employed with precaution in patients with heart disease.
